Table 1.
Characteristics of Participants by Insulin Resistance Status
| Characteristic | N (IR+/IR−) | IR+ | IR− | pa |
|---|---|---|---|---|
| Age (year), median [IQR] | 39/105 | 16.37 [14.52, 17.99] | 16.08 [13.99, 17.65] | .30 |
| Sex [Female, n (%] | 39/105 | 22 (56) | 53 (50) | .58 |
| Race/Ethnicity, n (%) | 39/105 | .62 | ||
| Hispanic | 10 (26) | 25 (33) | ||
| Black non-Hispanic | 27 (69) | 66 (63) | ||
| White/other non-Hispanic | 2 (5) | 4 (4) | ||
| Tanner stage, n (%) | 39/105 | .12 | ||
| 2–3 | 5 (13) | 28 (27) | ||
| 4–5 | 34 (87) | 77 (73) | ||
| Current CD4 (cells/mm3), median [IQR] | 38/94 | 563.50 [426.00, 864.00] | 620.50 [461.00, 777.00] | .90 |
| Current CD4 (cells/mm3), n (%) | 38/94 | .23 | ||
| <200 | 5 (13) | 5 (5) | ||
| 201–500 | 7 (18) | 25 (24) | ||
| >500 | 26 (67) | 64 (61) | ||
| Current CD4 (%), median [IQR] | 38/94 | 31.35 [25.00, 36.00] | 32.40 [25.10, 38.00] | .41 |
| Nadir CD4 (cells/mm3), median [IQR] | 39/105 | 268 [70, 443] | 328 [204, 454] | .068 |
| Nadir CD4 (cells/mm3), n (%) | 39/105 | .090 | ||
| <200 | 16 (41) | 24 (23) | ||
| 201–500 | 18 (46) | 60 (57) | ||
| ≥500 | 5 (13) | 21 (20) | ||
| Nadir CD4 (%), median [IQR] | 39/105 | 15.00 [4.80, 21.70] | 17.15 [10.00, 24.00] | .058 |
| Current log HIV RNA (copies/mL), median [IQR] | 35/96 | 1.73 [1.60, 3.13] | 2.30 [1.60, 3.53] | .49 |
| Peak log HIV RNA (copies/mL), median [IQR] | 39/105 | 5.78 [5.49, 5.88] | 5.50 [4.95, 5.87] | .002 |
| Cumulative duration of ARVs, (years), median [IQR] | 39/105 | |||
| ZDV | 3.47 [0.92, 6.49] | 3.31 [0.61, 7.85] | .77 | |
| D4T | 5.22 [1.46, 7.13] | 5.64 [0.00, 8.62] | .83 | |
| 3TC | 7.21 [3.98, 10.66] | 6.32 [3.29, 9.89] | .36 | |
| TDF | 1.38 [0.00, 3.56] | 0.00 [0.00, 1.83] | .061 | |
| BMI z-score, median [IQR] | 38/105 | 1.12 [0.57, 1.70] | 0.09 [−0.57, 0.73] | <.001 |
| Waist-to-hip ratio, median [IQR] | 35/101 | 0.90 [0.87, 0.97] | 0.86 [0.83, 0.91] | .002 |
a
Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables.
3TC, lamivudine; ARV, antiretrovirals; BMI, body mass index; D4T, stavudine; IQR, interquartile range; IR+, insulin-resistant case; IR−, insulin-sensitive control; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.